Document Detail

FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
MedLine Citation:
PMID:  20952484     Owner:  NLM     Status:  MEDLINE    
4-[5-(Pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (FYX-051) is a potent inhibitor of bovine milk xanthine oxidoreductase (XOR). Steady-state kinetics study showed that it initially behaved as a competitive-type inhibitor with a K(i) value of 5.7 × 10(-9) M, then after a few minutes it formed a tight complex with XOR via a Mo-oxygen-carbon atom covalent linkage, as reported previously (Proc Natl Acad Sci USA 101:7931-7936, 2004). Thus, FYX-051 is a hybrid-type inhibitor exhibiting both structure- and mechanism-based inhibition. The FYX-051-XOR complex decomposed with a half-life of 20.4 h, but the enzyme activity did not fully recover. This was found to be caused by XOR-mediated conversion of FYX-051 to 4-[5-(2-hydroxypyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (2-hydroxy-FYX-051), as well as formation of 6-hydroxy-4-[5-(2-hydroxypyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile (dihydroxy-FYX-051) and 4-[5-(2,6-dihydroxypyridin-4-yl)-1H-1,2,4-triazol-3-yl]-6-hydroxypyridine-2-carbonitrile (trihydroxy-FYX-051) during prolonged incubation for up to 72 h. A distinct charge-transfer band was observed concomitantly with the formation of the trihydroxy-FYX-051-XOR complex. Crystallographic analysis of the charge-transfer complex indicated that a Mo-nitrogen-carbon bond was formed between molybdenum of XOR and the nitrile group of trihydroxy-FYX-051. FYX-051 showed a potent and long-lasting hypouricemic effect in a rat model of potassium oxonate-induced hyperuricemia, and it seems to be a promising candidate for the clinical treatment of hyperuricemia.
Koji Matsumoto; Ken Okamoto; Naoki Ashizawa; Takeshi Nishino
Related Documents :
8588874 - Selective inhibition of cyclic amp-dependent protein kinase by amphiphilic triterpenoid...
1933404 - 1(2-benzoylethyl)pyridinium chloride: a new potent and selective inhibitor of bovine br...
18825534 - Cubebin and derivatives as inhibitors of mitochondrial complex i. proposed interaction ...
19845434 - Comparison of mechanism-based inhibition of human cytochrome p450 2c19 by ticlopidine, ...
12856314 - A potentially important excretory-secretory product of giardia lamblia.
12381154 - A trail of research revisted.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-15
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  336     ISSN:  1521-0103     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-16     Completed Date:  2011-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  95-103     Citation Subset:  IM    
Department of Biochemistry and Molecular Biology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan.
Data Bank Information
Bank Name/Acc. No.:
PDB/1FO4;  3AM9
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Binding, Competitive / drug effects
Crystallography, X-Ray
Nitriles / chemistry,  pharmacology*
Pyridines / chemistry,  pharmacology*
Rats, Wistar
Structure-Activity Relationship
Xanthine Dehydrogenase / antagonists & inhibitors*,  isolation & purification,  metabolism*
Reg. No./Substance:
0/FYX-051; 0/Nitriles; 0/Pyridines; EC Dehydrogenase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the bra...
Next Document:  Effects of graded heat stress on global left ventricular function and twist mechanics at rest and du...